- Home
- WINT vs PRFX Comparison
WINT vs PRFX Comparison
Compare WINT & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WINT
- PRFX
- Stock Information
- Founded
- WINT 1992
- PRFX 2007
- Country
- WINT United States
- PRFX Israel
- Employees
- WINT N/A
- PRFX N/A
- Industry
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- PRFX Biotechnology: Pharmaceutical Preparations
- Sector
- WINT Health Care
- PRFX Health Care
- Exchange
- WINT Nasdaq
- PRFX Nasdaq
- Market Cap
- WINT 3.6M
- PRFX 3.6M
- IPO Year
- WINT 1995
- PRFX 2020
- Fundamental
- Price
- WINT $0.57
- PRFX $2.06
- Analyst Decision
- WINT Hold
- PRFX Hold
- Analyst Count
- WINT 1
- PRFX 1
- Target Price
- WINT $350.00
- PRFX N/A
- AVG Volume (30 Days)
- WINT 264.4K
- PRFX 55.9K
- Earning Date
- WINT 05-16-2025
- PRFX 06-20-2025
- Dividend Yield
- WINT N/A
- PRFX N/A
- EPS Growth
- WINT N/A
- PRFX N/A
- EPS
- WINT N/A
- PRFX N/A
- Revenue
- WINT N/A
- PRFX N/A
- Revenue This Year
- WINT N/A
- PRFX N/A
- Revenue Next Year
- WINT N/A
- PRFX N/A
- P/E Ratio
- WINT N/A
- PRFX N/A
- Revenue Growth
- WINT N/A
- PRFX N/A
- 52 Week Low
- WINT $0.55
- PRFX $1.68
- 52 Week High
- WINT $737.44
- PRFX $18.17
- Technical
- Relative Strength Index (RSI)
- WINT 26.04
- PRFX 51.59
- Support Level
- WINT $0.67
- PRFX $1.93
- Resistance Level
- WINT $0.81
- PRFX $2.11
- Average True Range (ATR)
- WINT 0.06
- PRFX 0.10
- MACD
- WINT 0.01
- PRFX 0.03
- Stochastic Oscillator
- WINT 5.24
- PRFX 80.77
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.